Richard Mathias L, Lamas Bruno, Liguori Giuseppina, Hoffmann Thomas W, Sokol Harry
*INRA, UMR1319 Micalis, Jouy en Josas, France; †AgroParisTech, UMR Micalis, Jouy en Josas, France; ‡Inflammation-Immunopathology-Biotherapy Department, DHU i2B, Paris, France; §Sorbonne Universités - UPMC Univ Paris 06, INSERM ERL 1157, Avenir Team Gut Microbiota and Immunity, Paris, France; ‖Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; and ¶Department of Gastroenterology, Saint Antoine Hospital, Assistance Publique Hôpitaux de Paris and Paris VI University, Paris, France.
Inflamm Bowel Dis. 2015 Mar;21(3):656-65. doi: 10.1097/MIB.0000000000000261.
The prevalence of inflammatory bowel diseases (IBD) has been steadily increasing since 1960. They are widespread throughout Europe, North America, China, and Japan and are emerging as a global disease. The equilibrium among epithelial cells, the immune system, and the related microbiota seems to be paramount in ensuring the absence of these IBD. The role of bacteria in the setting of the gut microbiota has been thoroughly documented, but the role of fungi, which are less abundant, needs to be investigated. Our understanding of the fungal microbiota composition and its impact on IBD has greatly increased in the past 8 years. In this review, we compiled data obtained for the composition of fungal gut microbiota. Special attention was paid to the various effects of this microbial community on the IBD, i.e., the mechanisms and immune pathways involved in these interactions.
自1960年以来,炎症性肠病(IBD)的患病率一直在稳步上升。它们在欧洲、北美、中国和日本广泛存在,并正成为一种全球性疾病。上皮细胞、免疫系统和相关微生物群之间的平衡似乎对于确保不发生这些炎症性肠病至关重要。细菌在肠道微生物群中的作用已得到充分记录,但数量较少的真菌的作用尚需研究。在过去8年里,我们对真菌微生物群组成及其对炎症性肠病的影响的了解有了很大增加。在本综述中,我们汇总了关于肠道真菌微生物群组成的数据。我们特别关注了这个微生物群落对炎症性肠病的各种影响,即这些相互作用所涉及的机制和免疫途径。